Endeavor

New Treatment Combines Electric Fields and Immunotherapy to Improve Survival for Glioblastoma Patients

Study shows promising results for patients with inoperable tumors, offering hope for better outcomes in one of the most aggressive forms of brain cancer

Newly Approved CAR T-Cell Therapy Gives Acute Lymphoblastic Leukemia a New Personalized Option

Novel design and tumor-guided dosing may reduce side effects while maintaining encouraging efficacy

AutoNation Distributes Totes for Hope to Patients at Moffitt Cancer Center

Organization is also presenting sponsor for Miles for Moffitt on Nov. 23

Newly Approved Cell Therapy Afami-Cel Shows Long-Term Tumor Control in Synovial Sarcoma

Phase 2 clinical trial data suggests the engineered T cells can stay active in the body for more than three years

New Cancer Vaccine May Boost Immunotherapy in Treating Lung Cancer

Phase 2 trial results suggest IO102-IO103 combined with pembrolizumab may enhance response rates in advanced lung cancer

A Novel Class of Therapeutic Biologics Shows Promise for HPV-Related Head and Neck Cancer

Combining two treatments may improve outcomes for patients with HPV 16–positive disease

Moffitt Experts’ Study Aims to Improve TIL Therapy Process

Tumor-infiltrating lymphocyte therapy is FDA approved to treat melanoma.

New Combination Therapy Brings Hope to Bladder Cancer Patients

Oncolytic immunotherapy and immune checkpoint inhibitor found to be safe and effective in treating muscle-invasive bladder cancer

New Immunotherapy Strategy Shows Promise in Lung Cancer Treatment

Moffitt researchers advance a novel approach to boost the immune system’s ability to target lung cancer cells